Context Therapeutics Inc. — Q1 2022 Form 10-Q
Business context and reporting period. Clinical-stage biopharmaceutical company focused on therapies for cancers affecting women. This unaudited report covers the three months ended March 31, 2022; comparisons are with Q1 2021. The company reported no revenue and operates as a single business segment.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / comparator |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.35 million | $0.44 million |
| General and administrative expense | $2.09 million | $0.40 million |
| Operating loss | $3.44 million | $0.84 million |
| Net loss | $3.44 million | $0.89 million |
| Net loss per share, basic and diluted | $0.22 | $2.55 |
| Cash used in operating activities | $3.82 million | $1.72 million |
| Cash and cash equivalents, March 31 | $45.73 million | $49.64 million at Dec. 31, 2021 |
| Total liabilities, March 31 | $1.64 million | $3.03 million at Dec. 31, 2021 |
Gross profit and operating margins are not applicable because the company had no revenue. Cash, cash equivalents and restricted cash declined by $3.96 million during Q1; investing cash outflow was $35,000 and financing cash outflow was $102,000. The company had an accumulated deficit of $32.69 million and stockholders’ equity of $45.39 million at March 31. No debt was outstanding; the prior convertible notes had converted in 2021, and the PPP loan was forgiven in July 2021. Operating lease liabilities totaled approximately $124,000.
Material changes versus Q1 2021
- Net loss increased by $2.55 million, or 285%, as operating expenses rose substantially.
- R&D expense increased by $0.91 million, principally from ONA-XR manufacturing, CLDN6 preclinical work and clinical-trial costs, as well as higher staffing.
- G&A expense increased by $1.69 million, reflecting higher compensation and share-based compensation, insurance, professional and consulting fees, and public-company costs.
- Operating cash use increased by $2.11 million. Q1 2021 financing had provided $3.03 million from preferred-stock sales; Q1 2022 financing instead used $102,000 for offering costs.
- Weighted-average shares rose to 15.97 million from 349,235, reflecting the company’s 2021 corporate and financing transactions. Potentially dilutive securities were excluded from diluted loss per share as anti-dilutive.
Outlook, commentary and risks
- Management expected March 31 cash to fund operations into 2024; the liquidity note separately states cash was expected to fund projected operations for at least 12 months from issuance of the financial statements. Management cautions that estimates depend on assumptions and cash could be used sooner than expected.
- The company expects continued losses and rising R&D, G&A and capital needs, and says substantial additional financing will be needed. It had no credit facility or committed capital source. Additional financing may dilute shareholders or require unfavorable terms; insufficient funding could delay, reduce or terminate programs.
- ONA-XR programs include investigator-sponsored studies in endometrial, breast and ovarian granulosa-cell cancers. Preliminary data were expected in mid-2022 for one endometrial trial and in the second half of 2022 for several other studies. CLDN6xCD3 bispecific antibody candidate selection for IND-enabling studies was expected in the second half of 2022. These are forward-looking expectations, not guaranteed outcomes.
- Risks include clinical and regulatory uncertainty, manufacturing and third-party reliance, intellectual-property challenges, competition, recruiting and retention, and potential COVID-19-related trial-site, enrollment or vendor delays and added costs. The company said it could not quantify COVID-19’s future financial impact.
- Under the Tyligand agreements, further manufacturing scale-up milestones could trigger $2 million and $3 million payments; specified sales royalties also apply. Integral Molecular may receive up to $55.3 million in development and regulatory milestones, up to $130 million in sales milestones, and tiered royalties up to 12%, subject to the agreement terms.
- The company reported no material legal proceedings and no material changes to the risk factors in its 2021 Form 10-K. Management concluded disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether clinical-trial timelines and expected interim data were achieved, and the safety and efficacy evidence for ONA-XR and CLDN6xCD3.
- Actual cash burn and runway versus management’s “into 2024” estimate, including the assumptions behind projected development spending.
- Timing, availability and potential dilution or other terms of future financing.
- Manufacturing scale-up progress, related milestone obligations, and the effect of licensing and royalty commitments on future economics.
- Potential changes to clinical-trial plans or costs from COVID-19, vendors, enrollment, regulatory requirements or other development risks.